Skip to main content
SpringerLink
Log in
Book cover

Urological Oncology pp 663–676Cite as

Urachal and Urethral Cancer (Excluding Penile Cancer)

  • Chapter
  • First Online:

  • 1636 Accesses

Abstract

The urachus usually seals off and gets obliterated by 12–13 weeks and is seen as a fibrous cord between the apex of the bladder and umbilicus. However its remnants can persist and become malignant tumours, the commonest being adenocarcinoma. Urachal cancer accounts for 0.01 % of all cancers but due to its silent course it is likely to be advanced at the time of presentation. The diagnosis is made by cystoscopic examination and advanced imaging by CT or MRI. In early cases urachectomy with excision of umbilicus is adequate in controlling the disease. Advanced cases may need chemotherapy.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol. 2009;33(5):659–68.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Sheldon CA, Clayman RV, Gonzalez R, et al. Malignant urachal lesions. J Urol. 1984;131(1):1–8.

    CAS  PubMed  Google Scholar 

  3. Bruins HM, Visser O, Ploeg M, et al. The clinical epidemiology of urachal carcinoma: results of a large, population based study. J Urol. 2012;188(4):1102–7.

    Article  PubMed  Google Scholar 

  4. Begg RC. The colloid adenocarcinoma of the bladder vault arising from the epithelium of the urachal canal: with a critical survey of the tumors of the urachus. Br J Surg. 1931;18:422–46.

    Article  Google Scholar 

  5. Siefker-Radtke A. Urachal carcinoma: surgical and chemotherapeutic options. Expert Rev Anticancer Ther. 2006;6(12):1715–21.

    Article  CAS  PubMed  Google Scholar 

  6. Paner GP, Barkan GA, Mehta V, et al. Urachal carcinomas of the nonglandular type: salient features and considerations in pathologic diagnosis. Am J Surg Pathol. 2012;36(3):432–42.

    Article  PubMed  Google Scholar 

  7. Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer. 2006;107(4):712–20.

    Article  PubMed  Google Scholar 

  8. Kakizoe T, Matsumoto K, Andoh M, et al. Adenocarcinoma of urachus. Report of 7 cases and review of literature. Urology. 1983;21:360–6.

    Article  CAS  PubMed  Google Scholar 

  9. Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal carcinoma. Urology. 1985;26:218–21.

    Article  CAS  PubMed  Google Scholar 

  10. Henly DR, Farrow GM, Zincke H. Urachal cancer: role of conservative surgery. Urology. 1993;42(6):635–9.

    Article  CAS  PubMed  Google Scholar 

  11. Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003;169(4):1295–8.

    Article  PubMed  Google Scholar 

  12. Pinthus JH, Haddad R, Trachtenberg J, et al. Population based survival data on urachal tumors. J Urol. 2006;175(6):2042–7.

    Article  PubMed  Google Scholar 

  13. Logothetis CL, Samuels ML, Ogden S. Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin. Urology. 1985;26:252–5.

    Article  CAS  PubMed  Google Scholar 

  14. Siefker-Radtke A. Urachal adenocarcinoma: a clinician guide for treatment. Semin Oncol. 2012;39(5):619–24.

    Article  CAS  PubMed  Google Scholar 

  15. Herr HW, Bochner BH, Sharp D, et al. Urachal carcinoma: contemporary surgical outcomes. J Urol. 2007;178(1):74–8.

    Article  PubMed  Google Scholar 

  16. Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy. Br J Urol. 1998;82:835–41.

    Article  CAS  PubMed  Google Scholar 

  17. Ray B, Guinan PD. Primary carcinoma of the urethra. In: Javadpour N, editor. Principles and management of urologic cancer. Baltimore: Williams and Wilkins; 1979. p. 445–73.

    Google Scholar 

  18. Dalbagni G, Zhang ZF, Lacombe L, Herr HW. Male urethral carcinoma: analysis of treatment outcome. Urology. 1999;53:1126–32.

    Article  CAS  PubMed  Google Scholar 

  19. Colapinto V, Evans DH. Primary carcinoma of the male urethra developing after urethroplasty for stricture. J Urol. 1977;118:581–4.

    CAS  PubMed  Google Scholar 

  20. Mohan H, Bal A, Punia RP, et al. Squamous cell carcinoma of the prostate. Int J Urol. 2003;10:114–6.

    Article  PubMed  Google Scholar 

  21. Cupp MR, Malek RS, Goellner JR, et al. Detection of human papillomavirus DNA in primary squamous cell carcinoma of the male urethra. Urology. 1996;48(4):551–5.

    Article  CAS  PubMed  Google Scholar 

  22. Wiener JS, Liu ET, Walther PJ. Oncogenic human papillomavirus type 16 is associated with squamous cell cancer of the male urethra. Cancer Res. 1992;52(18):5018–23.

    CAS  PubMed  Google Scholar 

  23. Gandhi JS, Khurana A, Tewari A, et al. Clear cell adenocarcinoma of the male urethral tract. Indian J Pathol Microbiol. 2012;55(2):245–7.

    Article  PubMed  Google Scholar 

  24. Narayan P, Konety B. Surgical treatment of female urethral carcinoma. Urol Clin North Am. 1992;19(2):373–82.

    CAS  PubMed  Google Scholar 

  25. Kim SJ, MacLennan GT. Pathology page: tumours of the male urethra. J Urol. 2005;174:312.

    Article  PubMed  Google Scholar 

  26. Lands RH, Ange D, Hartman DL. Radiation therapy for classic Kaposi’s sarcoma presenting only on the glans penis. J Urol. 1992;147(2):468–70.

    CAS  PubMed  Google Scholar 

  27. Freeman JA, Esrig D, Stein JP, Skinner DG. Management of the patient with bladder cancer. Urethral recurrence. Urol Clin North Am. 1994;21:645–51.

    CAS  PubMed  Google Scholar 

  28. Erckert M, Stenzl A, Falk M, Bartsch G. Incidence of urethral tumour involvement in 910 men with bladder cancer. World J Urol. 1996;14:3–8.

    Article  CAS  PubMed  Google Scholar 

  29. Schellhammer RF, Whitmore Jr WF. Transitional cell carcinoma of the urethra in men having cystectomy for bladder cancer. J Urol. 1976;115:56–60.

    CAS  PubMed  Google Scholar 

  30. Thyavihally YB, Wuntkal R, Bakshi G, Uppin S, Tongaonkar HB. Primary carcinoma of female urethra: single center experience of 18 cases. Jpn J Clin Oncol. 2005;35:84–7.

    Article  PubMed  Google Scholar 

  31. Coloby PJ, Kakizoe T, Tobisu K, Sakamoto M. Urethral involvement in female bladder cancer patients. Mapping of 47 consecutive cystourethrectomy specimens. J Urol. 1994;152:1438–42.

    CAS  PubMed  Google Scholar 

  32. Chu AM. Female urethral carcinoma. Radiology. 1973;107:627–30.

    Article  CAS  PubMed  Google Scholar 

  33. Eng TY, Naguib M, Galang T, Fuller CD. Retrospective study of the treatment of urethral cancer. Am J Clin Oncol. 2003;26(6):558–62.

    Article  PubMed  Google Scholar 

  34. Hricak H, Secaf E, Buckley DW, et al. Female urethra: MR imaging. Radiology. 1991;178:527–35.

    Article  CAS  PubMed  Google Scholar 

  35. Israel GM, Lee VS, Resnick D, et al. Magnetic resonance evaluation of the urethra and lower genitourinary tract in symptomatic women. J Women’s Imag. 2002;4:165–72.

    Article  Google Scholar 

  36. Gourtsoyianni S, Hudolin T, Sala E, et al. MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. Clin Radiol. 2011;66:1072–8.

    Article  CAS  PubMed  Google Scholar 

  37. Dinney CP, Johnson PE, Swanson DA, et al. Therapy and prognosis for male urethral carcinoma: an update. Urology. 1994;43:506–14.

    Article  CAS  PubMed  Google Scholar 

  38. Zeidman EJ, Desmond P, Thompson I. Surgical treatment of carcinoma of the male urethra. Urol Clin North Am. 1992;19:359–72.

    CAS  PubMed  Google Scholar 

  39. Rabbani F. Prognostic factors in male urethral cancer. Cancer. 2011;117:2426–34.

    Article  PubMed  Google Scholar 

  40. Konnak JW. Conservative management of low-grade neoplasms of the male urethra: a preliminary report. J Urol. 1980;123:175–7.

    CAS  PubMed  Google Scholar 

  41. Smith Y, Hadway P, Ahmed S, et al. Penile-preserving surgery for male distal urethral carcinoma. BJU Int. 2007;100:82–7.

    Article  PubMed  Google Scholar 

  42. Ray B, Canto AR, Whitmore Jr WF. Experience with primary carcinoma of male urethra. J Urol. 1977;117:591–4.

    CAS  PubMed  Google Scholar 

  43. Bracken RB, Henry R, Ordonez N. Primary carcinoma of male urethra. South Med J. 1980;73:1003–5.

    Article  CAS  PubMed  Google Scholar 

  44. Kaplan GW, Bulkey GJ, Greyhack JT. Carcinoma of male urethra. J Urol. 1967;98:365–71.

    CAS  PubMed  Google Scholar 

  45. Donat SM, Cozzi PJ, Herr HW. Surgery of penile and urethral carcinoma. In: Walsh PC, Retik AB, Vaughn AD, Wein AJ, editors. Campbell’s urology. 8th ed. Philadelphia: Saunders; 2002. p. 2983–91.

    Google Scholar 

  46. Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for extravesical urinary tract tumors. J Urol. 1988;139:475–7.

    CAS  PubMed  Google Scholar 

  47. Licht MR, Klein EA, Bukowski R, et al. Combination radiation and chemotherapy for the treatment of squamous cell carcinoma of the male and female urethra. J Urol. 1995;153:1918–20.

    Article  CAS  PubMed  Google Scholar 

  48. Oberfield RA, Zinman LN, Leibenhaut M, et al. Management of invasive squamous cell carcinoma of the bulbomembranous male urethra with co-ordinated chemo-radiotherapy and genital preservation. Br J Urol. 1996;78:573–8.

    Article  CAS  PubMed  Google Scholar 

  49. Gheiler EL, Tefilli MV, Tiguert R, et al. Management of primary urethral cancer. Urology. 1998;52:487–93.

    Article  CAS  PubMed  Google Scholar 

  50. Dayyani F, Pettaway CA, Kamat AM, et al. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists. Urol Oncol. 2013;31(7):1171–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. DiMarco DS, DiMarco CS, Zincke H, et al. Surgical treatment for local control of female urethral carcinoma. Urol Oncol. 2004;22:404–9.

    Article  PubMed  Google Scholar 

  52. Grigsby PW, Corn BW. Localized urethral tumors in women: indications for conservative versus exenterative therapies. J Urol. 1992;147(6):1516–20.

    CAS  PubMed  Google Scholar 

  53. Cresswell J, Roberts JT, Neal DE. Urethral recurrence after radical radiotherapy for bladder cancer. J Urol. 2001;165(4):1135–7.

    Article  CAS  PubMed  Google Scholar 

  54. Clark PE, Stein JP, Groshen SG, Miranda G, et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004;172:1342–7.

    Article  PubMed  Google Scholar 

  55. Stein JP, Clark P, Miranda G, et al. Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol. 2005;173:1163–8.

    Article  PubMed  Google Scholar 

  56. Nieder AM, Sved PD, Gomez P, Kim SS, Manoharan M, Soloway MS. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology. 2004;64:950–4.

    Article  PubMed  Google Scholar 

  57. Hassan JM, Cookson MS, Smith Jr JA, Chang SS. Urethral recurrence in patients following orthotopic urinary diversion. J Urol. 2004;172:1338–41.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University Hospitals Coventry and Warwickshire NHS Trust, Warwickshire, UK

    Priyadarshi Kumar MB, BS, MRCS, MD, FRCS Urol

  2. Department of Urology, Homerton University Hospital, London, UK

    Vinod H. Nargund PhD, FRCSEd, FRCSUrol, FEBU

Authors
  1. Priyadarshi Kumar MB, BS, MRCS, MD, FRCS Urol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vinod H. Nargund PhD, FRCSEd, FRCSUrol, FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Priyadarshi Kumar MB, BS, MRCS, MD, FRCS Urol .

Editor information

Editors and Affiliations

  1. Department of Urology, Homerton University Hospital & Formerly St. Bartholomew's Hospital, London, United Kingdom

    Vinod H. Nargund

  2. Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina, USA

    Derek Raghavan

  3. Radiation Oncology, Cedars Sinai Cancer Center, Los Angeles, California, USA

    Howard M. Sandler

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Kumar, P., Nargund, V.H. (2015). Urachal and Urethral Cancer (Excluding Penile Cancer). In: Nargund, V., Raghavan, D., Sandler, H. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-482-1_38

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-482-1_38

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-481-4

  • Online ISBN: 978-0-85729-482-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation